FDA
-
-
-
-
-
-
-
TD Cowen: '10 Potential "Thome Run" Catalysts to Watch in 2025'
-
-
-
-
-
-
-
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2023
-
-
-
-
-
-
-
Xenon Pharmaceuticals (XENE) Announces Positive End-of-Phase 2 Meeting with the FDA
-
-
-
-
-
-
-
Xenon Pharmaceuticals Reports 2021 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2022
-
-
-
-
-
-
-
Xenon Pharmaceuticals (XENE) Phase 2b 'X-TOLE' Clinical Trial of XEN1101 for the Treatment of Focal Epilepsy Met its Primary Efficacy Endpoint
-
-
-
-
-
-
-
Xenon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

